Cerebral Salt Wasting: Diagnosis and Management in Neurocritical Care

Definition & Epidemiology

Cerebral salt wasting (CSW) is a hypovolemic hyponatraemic syndrome caused by renal sodium loss and diuresis that occurs in the setting of intracranial disease, most often after neurosurgical procedures, subarachnoid haemorrhage, or traumatic brain injury. 1
In neurosurgical patients, the reported prevalence of CSW can be as high as 50 %. 2

The pivotal diagnostic feature separating CSW from the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is patient volume status: CSW presents with clinical hypovolaemia (e.g., reduced skin turgor, dry mucous membranes, orthostatic hypotension, tachycardia, low central venous pressure, negative fluid balance, weight loss), whereas SIADH patients are euvolaemic or mildly hypervolaemic. [1][3]
When serum sodium falls below 131 mmol/L, the work‑up should include measurement of serum and urine osmolarity and serum uric acid (typically low in both conditions), together with meticulous fluid‑balance monitoring and physical examination for volume status. [1][3]
Routine measurement of ADH or natriuretic peptide levels is not recommended for differentiating CSW from SIADH because the results are inconsistent and do not reliably aid diagnosis. [1][3]

Untreated CSW‑related hyponatraemia in neurocritical patients is associated with severe cerebral oedema, altered mental status, and increased mortality. [2][4]
In patients with subarachnoid haemorrhage, CSW‑related hyponatraemia markedly raises the risk of cerebral vasospasm and subsequent infarction. 5

The primary therapeutic goal in CSW is restoration of intravascular volume and sodium balance, which contrasts with the fluid‑restriction approach used for SIADH. 1
Isotonic saline is the first‑line agent for volume replacement in most cases.
Hypertonic saline (3 % NaCl) is indicated for severe or symptomatic hyponatraemia. 6
Fludrocortisone, a mineralocorticoid that enhances renal sodium reabsorption, is employed in complicated or refractory CSW. [7][2]
Oral salt supplementation may be used in milder presentations.

Fluid restriction—the standard treatment for SIADH—must be avoided in subarachnoid haemorrhage patients with hyponatraemia, as it significantly increases the incidence of cerebral infarction. A retrospective analysis showed that the majority of patients managed with fluid restriction developed infarction, whereas normonatraemic controls had a substantially lower rate. [7][5]

Misdiagnosing CSW as SIADH and applying fluid restriction can precipitate cardiovascular collapse, worsen cerebral perfusion, and dramatically raise the risk of vasospasm and infarction in neurocritical patients. Careful physical examination and fluid‑balance assessment are essential to prevent this fatal error. 7

Up to 50 % of patients undergoing neurosurgical procedures develop cerebral salt wasting, indicating a high prevalence in this population. 8

In neurocritical patients, untreated CSW‑related hyponatremia is associated with severe cerebral edema, altered mental status, seizures, and increased mortality. 8
Across a broad range of primary disorders, mortality rates are significantly higher in hyponatremic patients compared with normonatremic counterparts. 8

Routine measurement of ADH or natriuretic peptide levels is not recommended, because the results are inconsistent and do not reliably differentiate CSW from SIADH. 9

Fludrocortisone (a mineralocorticoid that enhances renal sodium reabsorption) is indicated for complicated or refractory CSW. 9
Serum sodium correction should not exceed 10 mmol/L per day to avoid osmotic demyelination syndrome. (Supported by multiple studies) [9][10]

Fluid restriction—the standard therapy for SIADH—must be avoided in SAH patients with hyponatremia, as it markedly increases the incidence of cerebral infarction. 9
Fludrocortisone may be considered in SAH patients at risk of vasospasm (Class I evidence). 9
Hydrocortisone may be used to prevent natriuresis in SAH patients (Class I evidence). 9